classical-ml-drug-discovery
Build defensible molecular ML for drug discovery — QSAR, virtual screening, ADMET, toxicity, binding affinity, drug-target models — with Random Forest, SVM/SVR, and Gradient Boosting, plus dataset analysis, inductive conformal prediction, multi-model consensus, diversity-aware batch selection, and c
as observed 2026-09-08T10:18:19.295Z- Identifier
classical-ml-drug-discovery- Source
- ClawHub
- Version observed
- 1.4.5
- Source repository
- not published
- Repository observation
- No source repository listed
- First observed here
- 2026-08-28T22:06:34.671Z
- Observations recorded
- 3
- Installs (reported upstream)
- 2
- Weekly downloads (upstream)
- 587
Observation history
2026-09-08T10:18:19.295Z
Fields that differed: changelog latestVersion topics
| Field | Before | After |
|---|---|---|
changelog |
"- Removed the file: skill-card.md.\n- Updated SKILL.md to adjust the categories metadata (now includes \"Chemical Informatics categories: [research, development, knowledge] Drug D | "classical-ml-drug-discovery 1.4.5\n\n- Removed `skill-card.md` file.\n- Updated `SKILL.md`:\n - Fixed categories field to a valid flat list.\n - No changes to description or doc |
latestVersion |
"1.4.4" | "1.4.5" |
topics |
["cheminformatics","drug-discovery","machine-learning","qsar","virtual-screening"] | ["chemical-informatics-drug-discovery","machine-learning","qsar","virtual-screening"] |
2026-09-07T09:39:20.406Z
Fields that differed: changelog latestVersion
| Field | Before | After |
|---|---|---|
changelog |
"v1.3.2: token-efficiency optimization of SKILL.md (-40% per-execution tokens) and README (-73%); all 12 rules, decision tables, failure modes, and security behavior preserved." | "- Removed the file: skill-card.md.\n- Updated SKILL.md to adjust the categories metadata (now includes \"Chemical Informatics categories: [research, development, knowledge] Drug D |
latestVersion |
"1.3.2" | "1.4.4" |
Correction
If you maintain this extension and believe anything above is inaccurate, request a correction. Corrections are published, and disputed entries are marked as disputed while under review.